RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    NEXT STORY
    Predictive Genetic Testing & Consumer/Wellness Genomics: World Market Anticipated to Witness a CAGR of 13.9% Over 2019-2025
    PREV STORY
    Sharps Compliance Reports Fiscal 2019 Fourth Quarter Results
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Precision Therapeutics’ Skyline Medical Division Expands Presence in Australia with Three New STREAMWAY Systems at Wangaratta Hospital in Victoria

    MINNEAPOLIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or ...

    author_avatar
    NASDAQ Market News

    The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61% from 2018 to 2025

    author_avatar
    NASDAQ Market News

    $11 million grant to study life-threatening blood clots in trauma patients

    author_avatar
    NASDAQ Market News